U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H3N2O4.Li
Molecular Weight 162.0286
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LITHIUM OROTATE

SMILES

c1c(C(=O)O)nc(nc1[O-])O.[Li+]

InChI

InChIKey=IZJGDPULXXNWJP-UHFFFAOYSA-M
InChI=1S/C5H4N2O4.Li/c8-3-1-2(4(9)10)6-5(11)7-3;/h1H,(H,9,10)(H2,6,7,8,11);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Li
Molecular Weight 6.94
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H3N2O4
Molecular Weight 155.0885
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: http://healthdarts.com/lithium-orotate/ | http://www.orthomolecularproducts.com/file.aspx?DocumentId=1667

Lithium orotate consists of lithium, an alkali metal, and orotic acid, a compound produced naturally in the body. Lithium orotate is marketed as a dietary supplement. It has a “GRAS” status. The chronic administration of lithium helps to support healthy mood by modulating NMDA receptors in the brain. Lithium also alters sodium transport and interferes with other ion exchange mechanisms, altering nerve conduction. Lithium can replace sodium in extracellular fluid. Recommended applications are: supports balanced mood; modulates polarization of cell membranes; ameliorates headaches; reduces alcohol cravings; supports healthy brain aging. Typical side effects are muscle weakness, apathy, loss of appetite (from all of one human trial).

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rat. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Serenity

Approved Use

It is recommended to reduce alcohol cravings
Primary
Serenity

Approved Use

Lithium Orotate is used in certain patients with the mental depression.
Primary
Serenity

Approved Use

Lithium Orotate is used to treat mania that is part of bipolar disorder (manic-depressive illness).
PubMed

PubMed

TitleDatePubMed
The clinical applications of lithium orotate. A two years study.
1973
Lithium orotate, carbonate and chloride: pharmacokinetics, polyuria in rats.
1976 Apr
Lithium orotate in the treatment of alcoholism and related conditions.
1986 Mar-Apr
Patents

Sample Use Guides

Three to four capsules a day (120 mg in one capsule), taken in daily dosages with meals.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:41:57 UTC 2021
Edited
by admin
on Sat Jun 26 10:41:57 UTC 2021
Record UNII
L2N7Z24B30
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LITHIUM OROTATE
VANDF   WHO-DD  
Common Name English
LITHIUM OROTATE [VANDF]
Common Name English
LITHIUM OROTATE [WHO-DD]
Common Name English
4-PYRIMIDINECARBOXYLIC ACID, 1,2,3,6-TETRAHYDRO-2,6-DIOXO-, LITHIUM SALT (1:1)
Common Name English
Classification Tree Code System Code
DSLD 499 (Number of products:145)
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
Code System Code Type Description
EPA CompTox
5266-20-6
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
FDA UNII
L2N7Z24B30
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
WIKIPEDIA
Lithium orotate
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
MESH
C016539
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
CAS
5266-20-6
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
PUBCHEM
23686432
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
ECHA (EC/EINECS)
226-081-4
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
EVMPD
SUB130574
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY
RXCUI
28815
Created by admin on Sat Jun 26 10:41:57 UTC 2021 , Edited by admin on Sat Jun 26 10:41:57 UTC 2021
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE